Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks African Distribution Agreement

NEW YORK – Mobidiag today announced that it has signed an exclusive agreement with Pro Med Diagnostics for the distribution of its Amplidiag and Novodiag products in African countries, including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, and Uganda.

Tuomas Tenkanen, CEO of Mobidiag, said in a statement that Africa "represents a fast growing market for diagnostic products with enormous growth potential."

Mobidiag is focused on continuing to develop its distributor network as part of its strategy to make its "IVD tests and instruments accessible to customers in centralized and decentralized settings around the world," he said, adding that Pro Med Diagnostics has a "strong background in molecular diagnostics and an extensive customer network."

Espoo, Finland-based Mobidiag markets its Amplidiag and Novodiag molecular diagnostic systems and assays used for the detection of infectious diseases and to address the spread of antimicrobial resistance by rapid detection of pathogens and potential resistance to antibiotics.

The Novodiag automated, cartridge-based system uses real-time PCR and microarray technology to detect infectious diseases and antibiotic resistance, delivering results in approximately one hour. The Amplidiag automated system does batch nucleic acid extraction and PCR plate setup from stool samples.

In June, Mobidiag announced that it has launched a joint venture with Autobio Diagnostics, a leading Chinese clinical diagnostics company, to commercialize its Novodiag system and infectious disease assays in China.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.